The report "Rat Model Market by Type (Outbred, Knockout, Conditioned], Technology (Microinjection, Embryonic Stem Cells), Application (Toxicology, Oncology, CNS), Service (Breeding, Cryopreservation, Quarantine) & Care Products (Cages, Bedding, Feed) - Forecasts to 2020", analyzes and studies the major market drivers, threats, and barriers in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

http://www.marketsandmarkets.com/Market-Reports/rat-model-market-76036494.html

Early buyers will receive 10% customization on reports.
Major players in the rat model market include Charles River Laboratories (U.S.), Taconic Biosciences, Inc. (U.S.), Janvier Labs (France), genOway S.A. (France), Covance, Inc. (U.S.), Harlan Laboratories, Inc. (U.S.), SAGE Labs (U.S.), Transposagen Biopharmaceuticals, Inc. (U.S.), Biomedical Research Models, Inc. (U.S.), and Transviragen Inc.

Download PDF brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=76036494

However, China is expected to witness highest growth in the rat model market, followed by Germany, during the forecast period. A number of factors such as international alliances for R&D activities, increasing investments in government and private sectors in the life sciences sector, and less stringent laws (as compared to developed markets) are driving the growth of the Chinese rat model market.
Request sample of this report@ http://www.marketsandmarkets.com/requestsample.asp?id=76036494

The major factors propelling the growth of the rat model market include the introduction of transgenic rat models, growing biomedical and translational research, ongoing preclinical activities in life sciences, growing field of personalized medicine, growing biosimilars market, and increasing government investments and funds that have stimulated the usage of advanced rat models in the biotechnology and pharmaceutical industries. Furthermore, research into cancer and neurology has increased the application areas of rat models.
The U.S. accounts for the largest share of the rat model market. This large share can be attributed to the growing epidemiology of diseases and simultaneous investments in the development of rat models, revised funding plans by the NIH to enhance the reproducibility of results in preclinical tests, increasing preclinical services for biosimilars, growing biomedical research, and increasing preclinical activities by CROs and pharmaceutical industries.